A non-profit pharmaceutical organization that’s based out of the University of Alberta is ramping up its efforts to produce ventilator drugs in anticipation of possible shortages.
Applied Pharmaceutical Innovation normally works with researchers to move viable drug ideas into the clinical trial phase, but as the COVID-19 situation has worsened, the organization is switching gears to produce drugs that it believes will soon be in short supply. “A lot of the respirator therapies that are needed for patients that are in intensive care units require that they be on certain drugs through an IV drip in order for them to be on the ventilator,” Andrew MacIsaac, the CEO of Applied Pharmaceutical Innovation, said. “So while a lot of public attention